{
  "id": 173453,
  "title": "Attovia extends biotech IPO streak with $289M listing for three I&I drugs",
  "url": "https://urgent.news/2026/08/05/attovia-extends-biotech-ipo-streak-with-289m-listing-for-three-i-i",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-05T11:00:13.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/attovia-extends-biotech-ipo-streak-with-289m-listing-for-three-ii-drugs/"
  },
  "original_language": "en",
  "account": null,
  "summary": "For the first time since the winter of 2025, the biotech industry is celebrating three consecutive weeks of initial public offerings. Attovia Therapeutics, an immunology and inflammation (I&I) biotech, extended the drug development industry's sizzling ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "BioPharma Dive",
        "title": "Attovia adds to biotech IPO momentum with $289M offering",
        "url": "https://urgent.news/2026/08/05/attovia-adds-to-biotech-ipo-momentum-with-289m-offering",
        "published": "2026-08-05T16:05:25.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}